Liquidia Revenue Growth Rates (LQDA), Current and Historic Growth - CSIMarket
CSIMarket
 


Liquidia Corporation  (NASDAQ: LQDA)
 

LQDA's Revenue Growth by Quarter and Year

Liquidia's Revenue results by quarter and year




LQDA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 171.68
1st Quarter March 132.87
FY 304.55

LQDAs Annual Revenue
Liquidia's Revenue in the fiscal year 2025 $ 158.32 millions
Liquidia's Revenue in the fiscal year 2024 $ 14.00 millions
Liquidia's Revenue in the fiscal year 2023 $ 17.49 millions
Liquidia's Revenue in the fiscal year 2022 $ 15.94 millions
Liquidia's Revenue in the fiscal year 2021 $ 12.85 millions




LQDA Revenue second quarter 2026 Y/Y Growth Comment
Liquidia Corporation achieved in the second quarter 2026, above Company average Revenue surge of 1842.07% year on year, to $ 171.68 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue growth. While Liquidia Corporation' s Revenue doubling of 1842.07% ranks overall at the positon no. 463 in the second quarter 2026.




LQDA Revenue ( Y/Y Growth %) 2026
2025 2024 2023
4th Quarter December - 3051.37 % -35.54 % -15.49 %
3rd Quarter September - 1121.12 % 20.92 % 16.09 %
2nd Quarter June 1842.07 % 141.53 % -23.59 % 22.19 %
1st Quarter March 4158.65 % 5.05 % -33.85 % 28.65 %
FY   - 1030.86 % -19.95 % -

Financial Statements
Liquidia's second quarter 2026 Revenue $ 171.68 millions LQDA's Income Statement
Liquidia's second quarter 2025 Revenue $ 8.84 millions Quarterly LQDA's Income Statement


LQDA Revenue (Quarter on Quarter Growth %)

2026
2025 2024 2023
4th Quarter December - 69.34 % -34.38 % 23.1 %
3rd Quarter September - 514.71 % 21.58 % -23.17 %
2nd Quarter June 29.21 % 183.33 % 23.23 % 6.68 %
1st Quarter March 44.39 % 6.85 % -34.44 % -16.23 %
FY (Year on Year)   - 1030.86 % -19.95 % -




Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #114
Overall #463

Revenue Y/Y Growth Statistics
High Average Low
2233.65 % 353.92 % -19.97 %
(Jun 30 2026)   (Dec 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #114
Overall #463
Revenue Y/Y Growth Statistics
High Average Low
2233.65 % 353.92 % -19.97 %
(Jun 30 2026)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Liquidia's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
514.94 % 39.31 % -100 %
(Sep 30 2025)  


LQDA's II. Quarter Q/Q Revenue Comment
Liquidia Corporation achieved in the II. Quarter 2026 below company average Revenue jump of 29.21% quarter on quarter, to $ 171.68 millions.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Liquidia's Revenue growth quarter on quarter, overall rank is 378.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #378
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #378
Revenue Q/Q Growth Statistics
High Average Low
514.94 % 39.31 % -100 %
(Sep 30 2025)  


LQDA's II. Quarter Q/Q Revenue Comment
Liquidia Corporation achieved in the II. Quarter 2026 below company average Revenue jump of 29.21% quarter on quarter, to $ 171.68 millions.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Liquidia's Revenue growth quarter on quarter, overall rank is 378.


Liquidia's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending
(Mar 31 2026)
12 Months Ending
(Dec 31 2025)
12 Months Ending
(Sep 30 2025)
12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 450.91 $ 288.07 $ 158.32 $ 69.22 $ 19.32
Y / Y Revenue Growth (TTM) 2233.65 % 1936.66 % 1031.18 % 343.41 % 30.2 %
Year on Year Revenue Growth Overall Ranking # 559 # 2299 # 2342 # 1396 # 2550
Seqeuential Revenue Change (TTM) 56.53 % 81.95 % 128.73 % 258.22 % 36.61 %
Seq. Revenue Growth (TTM) Overall Ranking # 463 # 1797 # 2224 # 1581 # 2569


Cumulative Revenue growth Comment
With 2233.65% annual Revenue growth, Liquidia Corporation would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 126 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 559, from total ranking in previous quarter at 2299.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 127
Overall # 559

Revenue TTM Y/Y Growth Statistics
High Average Low
2233.65 %
353.92 %
-19.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 114
S&P 500 # 463
Cumulative Revenue growth Comment
With 2233.65% annual Revenue growth, Liquidia Corporation would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 126 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 559, from total ranking in previous quarter at 2299.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 127
Overall # 559

Revenue TTM Y/Y Growth Statistics
High Average Low
2233.65 %
353.92 %
-19.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 114
S&P 500 # 463




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LQDA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Aligos Therapeutics Inc 2,778.55%$ 2,778.549 millions
Crinetics Pharmaceuticals Inc 2,336.28%$ 2,336.275 millions
Tao Synergies Inc 2,136.90%$ 2,136.901 millions
Liquidia Corporation1,842.73%$ 1,842.729 millions
Verastem Inc 1,775.43%$ 1,775.433 millions
EBR Systems, Inc.1,453.92%$ 1,453.919 millions
Safe Pro Group Inc 1,336.15%$ 1,336.152 millions
Capforce Inc 1,150.00%$ 1,150.000 millions
Crispr Therapeutics Ag1,041.37%$ 1,041.368 millions
Arvinas Inc 1,014.73%$ 1,014.732 millions


About Liquidia Revenue Growth Rates (LQDA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.